vs
Side-by-side financial comparison of BioNTech SE (BNTX) and CIMPRESS plc (CMPR). Click either name above to swap in a different company.
BioNTech SE is the larger business by last-quarter revenue ($1.5B vs $1.0B, roughly 1.5× CIMPRESS plc). CIMPRESS plc runs the higher net margin — 4.7% vs -1.9%, a 6.6% gap on every dollar of revenue.
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
Cimpress plc is an American Irish-domiciled multinational technology company that invests in and operates a wide variety of businesses that use mass customization to configure and produce small quantities of individually customized goods. Those products are sold to small businesses, graphic designers and consumers through a number of customer-facing brands that Cimpress operates.
BNTX vs CMPR — Head-to-Head
Income Statement — Q3 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.5B | $1.0B |
| Net Profit | $-28.7M | $49.3M |
| Gross Margin | — | 46.8% |
| Operating Margin | -3.1% | 8.5% |
| Net Margin | -1.9% | 4.7% |
| Revenue YoY | — | 11.0% |
| Net Profit YoY | — | -19.2% |
| EPS (diluted) | — | $1.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $1.0B | ||
| Q3 25 | $1.5B | $863.3M | ||
| Q2 25 | $260.8M | — | ||
| Q3 24 | $1.2B | — |
| Q4 25 | — | $49.3M | ||
| Q3 25 | $-28.7M | $7.6M | ||
| Q2 25 | $-386.6M | — | ||
| Q3 24 | $198.1M | — |
| Q4 25 | — | 46.8% | ||
| Q3 25 | — | 46.7% | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — |
| Q4 25 | — | 8.5% | ||
| Q3 25 | -3.1% | 5.7% | ||
| Q2 25 | -192.1% | — | ||
| Q3 24 | 0.8% | — |
| Q4 25 | — | 4.7% | ||
| Q3 25 | -1.9% | 0.9% | ||
| Q2 25 | -148.2% | — | ||
| Q3 24 | 15.9% | — |
| Q4 25 | — | $1.95 | ||
| Q3 25 | — | $0.30 | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $258.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $-530.7M |
| Total Assets | — | $2.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $258.0M | ||
| Q3 25 | — | $200.5M | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — |
| Q4 25 | — | $-530.7M | ||
| Q3 25 | — | $-571.3M | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — |
| Q4 25 | — | $2.1B | ||
| Q3 25 | — | $2.0B | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $164.7M |
| Free Cash FlowOCF − Capex | — | $139.5M |
| FCF MarginFCF / Revenue | — | 13.4% |
| Capex IntensityCapex / Revenue | — | 2.4% |
| Cash ConversionOCF / Net Profit | — | 3.34× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $164.7M | ||
| Q3 25 | — | $25.1M | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — |
| Q4 25 | — | $139.5M | ||
| Q3 25 | — | $-1.3M | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — |
| Q4 25 | — | 13.4% | ||
| Q3 25 | — | -0.1% | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — |
| Q4 25 | — | 2.4% | ||
| Q3 25 | — | 3.1% | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — |
| Q4 25 | — | 3.34× | ||
| Q3 25 | — | 3.28× | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BNTX
Segment breakdown not available.
CMPR
| Vista | $532.8M | 51% |
| Print Brothers | $219.9M | 21% |
| National Pen | $150.9M | 14% |
| The Print Group | $115.2M | 11% |
| All Other Businesses | $67.2M | 6% |
